Therapeutic Efficacy and Mechanisms of Mesenchymal Stem Cells and Their Exosomes in the Treatment of Ocular Graft-Versus-Host Disease.

IF 1.9 3区医学 Q2 OPHTHALMOLOGY

Cornea Pub Date : 2025-03-27 DOI:10.1097/ICO.0000000000003868

Chenxi Ye, Shuwan Liu, Jing Hong

{"title":"Therapeutic Efficacy and Mechanisms of Mesenchymal Stem Cells and Their Exosomes in the Treatment of Ocular Graft-Versus-Host Disease.","authors":"Chenxi Ye, Shuwan Liu, Jing Hong","doi":"10.1097/ICO.0000000000003868","DOIUrl":null,"url":null,"abstract":"Purpose: To provide a comprehensive overview of the clinical manifestations, pathophysiology, and current treatments of ocular graft-versus-host disease (oGVHD), and to explore the therapeutic potential of mesenchymal stem cells (MSCs) and their exosomes (MSC-Exos) as novel treatments.Methods: A literature review was conducted using major databases (PubMed, Web of Science, Scopus) to identify studies published between 2000 and 2024. The focus was on clinical trials, case series, and experimental studies related to oGVHD. Data were synthesized to summarize current knowledge.Results: oGVHD affects 40% to 60% of Hematopoietic Stem Cell Transplantation recipients, causing symptoms such as dryness, irritation, and vision impairment. Current treatments often fail to provide long-term relief and may cause significant side effects. MSCs and MSC-Exos offer a promising alternative because of their immunosuppressive and regenerative properties. Preclinical and clinical studies have demonstrated their safety and efficacy in improving oGVHD symptoms and promoting corneal health.Conclusions: MSCs and MSC-Exos show promise in treating oGVHD, with potential to improve symptoms and promote tissue repair. Further research is needed to establish their long-term safety and efficacy.","PeriodicalId":10710,"journal":{"name":"Cornea","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cornea","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICO.0000000000003868","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To provide a comprehensive overview of the clinical manifestations, pathophysiology, and current treatments of ocular graft-versus-host disease (oGVHD), and to explore the therapeutic potential of mesenchymal stem cells (MSCs) and their exosomes (MSC-Exos) as novel treatments.

Methods: A literature review was conducted using major databases (PubMed, Web of Science, Scopus) to identify studies published between 2000 and 2024. The focus was on clinical trials, case series, and experimental studies related to oGVHD. Data were synthesized to summarize current knowledge.

Results: oGVHD affects 40% to 60% of Hematopoietic Stem Cell Transplantation recipients, causing symptoms such as dryness, irritation, and vision impairment. Current treatments often fail to provide long-term relief and may cause significant side effects. MSCs and MSC-Exos offer a promising alternative because of their immunosuppressive and regenerative properties. Preclinical and clinical studies have demonstrated their safety and efficacy in improving oGVHD symptoms and promoting corneal health.

Conclusions: MSCs and MSC-Exos show promise in treating oGVHD, with potential to improve symptoms and promote tissue repair. Further research is needed to establish their long-term safety and efficacy.

查看原文本刊更多论文

间充质干细胞及其外泌体治疗眼部移植物抗宿主病的疗效及机制

目的：全面概述眼移植物抗宿主病（oGVHD）的临床表现、病理生理学和当前治疗方法，并探索间充质干细胞（MSCs）及其外泌体（MSC-Exos）作为新型治疗方法的治疗潜力：方法：利用主要数据库（PubMed、Web of Science、Scopus）进行文献综述，以确定2000年至2024年间发表的研究。重点是与 oGVHD 相关的临床试验、系列病例和实验研究。结果：40%到60%的造血干细胞移植受者会受到oGVHD的影响，导致干燥、刺激和视力受损等症状。目前的治疗方法往往无法长期缓解症状，并可能产生严重的副作用。间充质干细胞和间充质干细胞-Exos 具有免疫抑制和再生特性，是一种很有前景的替代疗法。临床前和临床研究证明，它们在改善oGVHD症状和促进角膜健康方面具有安全性和有效性：结论：间充质干细胞和间充质干细胞-Exos在治疗oGVHD方面前景看好，具有改善症状和促进组织修复的潜力。要确定它们的长期安全性和有效性，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cornea 医学-眼科学

CiteScore

5.20

自引率

10.70%

发文量

354

审稿时长

3-6 weeks

期刊介绍： For corneal specialists and for all general ophthalmologists with an interest in this exciting subspecialty, Cornea brings together the latest clinical and basic research on the cornea and the anterior segment of the eye. Each volume is peer-reviewed by Cornea''s board of world-renowned experts and fully indexed in archival format. Your subscription brings you the latest developments in your field and a growing library of valuable professional references. Sponsored by The Cornea Society which was founded as the Castroviejo Cornea Society in 1975.